Understanding how adenosine affects SIV infection and gut health
Official title: Probing the role of adenosine pathway in SIV pathogenesis
Funded at University of Pittsburgh at Pittsburgh · NIH-11089392 · Data updated 2026-11-12
This study is looking at how a molecule called adenosine affects the immune system in non-human primates with SIV, which is similar to HIV, to see if adjusting adenosine levels can help reduce gut problems caused by the infection.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project start | June 20, 2023 |
| Project end | May 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $771,534 |
| NIH project number | 5R01AI179317-03 |
| Project ID | NIH-11089392 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who are infected with SIV or HIV and are experiencing gut-related health issues.
✕Less likely to help
Patients who are not infected with SIV or HIV or who do not have any gut dysfunction may not benefit from this research.
What this research studies
This research investigates the role of adenosine, a molecule that helps regulate immune responses, in the context of SIV infection, which is similar to HIV. By studying non-human primates, the researchers aim to understand how different levels of adenosine in the gut can influence the severity of gut dysfunction during SIV infection. The project will involve examining the expression of specific enzymes that produce adenosine and how these levels correlate with immune responses and inflammation. The ultimate goal is to explore whether targeting the adenosine pathway could help protect against gut-related issues caused by SIV.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for preventing or treating gut dysfunction in patients with SIV or HIV.
How similar studies have gone: Previous studies have shown that targeting immune pathways similar to the adenosine pathway can lead to improvements in managing viral infections, suggesting potential for success in this approach.
Where this research is happening
-
University of Pittsburgh at Pittsburgh
Pittsburgh, United States Active
Researchers
- Principal investigator: Vasile Pandrea, Ivona — University of Pittsburgh at Pittsburgh
- Study coordinator: Vasile Pandrea, Ivona
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.